|[September 11, 2013]
Research and Markets: p53 Signaling Pathway in Cancer Drug Pipeline 2013 - Updated Report
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/vznpzg/p53_signaling)
has announced the addition of the "p53
Signaling Pathway in Cancer Drug Pipeline" report to their
p53 activation is induced by a number of stress signals, including DNA
damage, oxidative stress and activated oncogenes. The p53 protein is
employed as a transcriptional activator of p53-regulated genes. This
results in three major outputs; cell cycle arrest, cellular senescence
or apoptosis. Other p53-regulated gene functions communicate with
adjacent cells, repair the damaged DNA or set up positive and negative
feedback loops that enhance or attenuate the functions of the p53
protein and integrate these stress responses with other signal
There are today 95 companies plus partners developing 85 p53 sinaling
pathway targeting drugs in 248 developmental projects in cancer. In
addition, there are 2 suspended drugs and the accumulated number of
ceased drugs over the last years amount to another 55 drugs. P53
Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and
gives you a progress analysis on each one of them. Identified drugs are
linked to 67 different targets. All included targets have been
cross-referenced for the presence of mutations associated with human
cancer. To date 65 out of the 65 studied drug targets so far have been
recorded with somatic mutations. The software application lets you
narrow in on these mutations and links out to the mutational analysis
for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application
by 31 classifications of molecular function and with pathway referrals
to BioCarta, KEGG, NCI-Nature and NetPath.
Reasons To Buy
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines
For more information visit http://www.researchandmarkets.com/research/vznpzg/p53_signaling.
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]